Pharmaceutical technology can turn a traditional drug, dexamethasone into a first-line ocular medicine. A global perspective and future trends

详细信息    查看全文

• 作者：Javier Rodrí ; guez Villanueva^a ; ^b ; ^{javier.rodriguezv@edu.uah.es} ; Laura Rodrí ; guez Villanueva^b ; Manuel Guzmá ; n Navarro^a ; ^b
• 关键词：Dexamethasone ; Sustained release systems ; Implants ; Microparticles ; Nanoparticles ; Dendrimers ; Ocular carriers
• 刊名：International Journal of Pharmaceutics
• 出版年：2017
• 出版时间：10 January 2017
• 年：2017
• 卷：516
• 期：1-2
• 页码：342-351
• 全文大小：1817 K
• 卷排序：516

文摘

Dexamethasone is one of the most prescribed glucocorticoids. It is effective and safe in the treatment of a wide variety of ocular conditions, including anterior and posterior segment inflammation. However, its half-life in the vitreous humor is very short, which means that it typically requires frequent administrations, thus reducing patient adherence and causing therapeutic failure. Innovative dexamethasone delivery systems have been designed in an attempt to achieve sustained release and targeting. The FDA has approved dexamethasone implants for the treatment of macular edema secondary to retinal vein occlusion and posterior segment noninfectious uveitis. Lenses, micro- and nanoparticles, liposomes, micelles and dendrimers are also proving to be adequate systems for maintaining optimal dexamethasone levels in the site of action. Pharmaceutical technology is turning a classical drug, dexamethasone, into a fashionable medicine.